Show simple item record

dc.contributor.authorHuen, A
dc.contributor.authorPorcu, P
dc.contributor.authorHudgens, S
dc.contributor.authorQuaglino, P
dc.contributor.authorCowan, Richard A
dc.contributor.authorFloden, L
dc.contributor.authorTsianakas, A
dc.contributor.authorLeoni, M
dc.contributor.authorDale, S
dc.contributor.authorDuvic, M
dc.date.accessioned2018-11-12T14:38:59Z
dc.date.available2018-11-12T14:38:59Z
dc.date.issued2018-09
dc.identifier.citationQuality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC. 2018, 18:S289 Clin Lymphoma Myeloma Leuken
dc.identifier.issn21522650
dc.identifier.doi10.1016/j.clml.2018.07.228
dc.identifier.urihttp://hdl.handle.net/10541/621315
dc.language.isoenen
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S2152265018309777en
dc.rightsArchived with thanks to Clinical Lymphoma Myeloma and Leukemiaen
dc.titleQuality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMD Anderson Cancer Center, Houston, Texasen
dc.identifier.journalClinical Lymphoma Myeloma and Leukemiaen


Files in this item

This item appears in the following Collection(s)

Show simple item record